BRAINTREE, Ma., June 16 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today at the annual meeting of the Plasma Protein Therapeutics Association the launch of a plasma collection software for its PCS(R)2 plasma collection system that reduces plasma donation time by 20%.
Stephen Swenson, General Manager of Global Plasma for Haemonetics, said, "This new software system, with its faster donation times, combined with our recently launched information technology platforms that automate center operations, are significant enhancements to our product offerings. These systems help our plasma customers to better leverage their plasma collection infrastructure by increasing donor throughput and also provide the donor with a more positive donation experience."
"As the global leader in blood management solutions, we are pleased to be continually strengthening our product suite with products, information technology platforms, and business services for blood collectors and hospitals to improve patient outcomes," he added.
The PCS2 software was 510(k) cleared by the U.S. Food and Drug Administration on May 28, 2008. The software can be used with existing PCS2 devices so no device replacement or additional operator training is required. The product will be launched in limited market release, with full market release expected by year end.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to
providing innovative blood management solutions for our customers.
Together, our devices and consumables, information technology platforms,
and consulting services deliver a suite of business solutions to help our
customers improve clinical outcomes and reduce the cost of healthcare for
blood collectors, hospitals, and patients around the world. Our
technologies address important medical markets: blood and plasma component
collection, the surgical suite, and hospital transfusion services. To learn
more about Haemonetics, visit our web site at http://www.haemonetics.com .
Tel. (781) 356-9517
Alt. Tel. (617) 320-2401
|SOURCE Haemonetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved